- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07470320
Placentabiologie in Gezondheid en Ziekte
Placentale Biologie in Gezondheid en Ziekte
Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.
A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.
This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.
Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Professor Manu Vatish
- Telefoonnummer: +441865 221009
- E-mail: manu.vatish@wrh.ox.ac.uk
Studie Locaties
-
-
-
Oxford, Verenigd Koninkrijk
- Werving
- Oxford University Hospitals NHS Foundation Trust
-
Contact:
- Clinical Research Group
- Telefoonnummer: +441865 221107
- E-mail: clinicalresearchgroup@wrh.ox.ac.uk
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.
Participants will include:
- Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
- Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
- Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
- Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.
Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.
Beschrijving
Inclusion Criteria:
-
Female, aged 18 years or above
-
Willing and able to give informed consent for participation in the study
-
Able to read and understand written and spoken English to comprehend study materials and give informed consent
-
Non-pregnant women in good general health OR pregnant women who fall into one of the following:
- Healthy pregnancy
- Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
- Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
- Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
- Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies
Exclusion Criteria:
- Non-pregnant participants with active health conditions that could confound study outcomes
- Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: OTHER
- Tijdsperspectieven: OTHER
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Zwangere vrouwen bij wie pre-eclampsie is vastgesteld
|
There are no interventions for this study |
|
Zwangere vrouwen bij wie zwangerschapsdiabetes is vastgesteld
|
There are no interventions for this study |
|
Zwangere vrouwen bij wie foetale groeivertraging is vastgesteld
|
There are no interventions for this study |
|
Gezonde zwangere vrouwen
|
There are no interventions for this study |
|
Gezonde niet-zwangere vrouwen
|
There are no interventions for this study |
|
Zwangere vrouwen met een aanleg voor pre-eclampsie
|
There are no interventions for this study |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
Tijdsspanne: Baseline and at delivery
|
Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles |
Baseline and at delivery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quantitative and qualitative differences in inflammatory immune cells
Tijdsspanne: baseline and delivery
|
Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured |
baseline and delivery
|
|
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
Tijdsspanne: Baseline and delivery
|
Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions |
Baseline and delivery
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Endocriene systeemziekten
- Vaatziekten
- Hart-en vaatziekten
- Pathologische processen
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Metabole ziekten
- Zwangerschap Complicaties
- Glucosemetabolismestoornissen
- Suikerziekte
- Foetale ziekten
- Groeistoornissen
- Hypertensie
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Diabetes, zwangerschap
- Pre-eclampsie
- Foetale groeivertraging
- Hypertensie, door zwangerschap veroorzaakt
Andere studie-ID-nummers
- 18939
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .